Ivabradine: The evidence of its therapeutic impact in angina

Core Evidence

Volumn 3, Issue 1, 2008, Pages 1-12

  Marquis Gravel, Guillaume ^a   Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Evidence; Ivabradine; Outcomes; Stable angina pectoris; Treatment

Indexed keywords

EID: 80052892935     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.3355/ce.2008.008     Document Type: Review

References (56)

1. AHA (American Heart Association). Heart disease and stroke statistics. 2008. Available at: http://www.americanheart.org/presenter.jhtml?identifier= 3000090 (accessed February 2008).
2. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet. 1991;338:1036-1039.
3. Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817-823. (Pubitemid 36241038)
4. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996;51:792-819.
5. Campeau L. Letter: grading of angina pectoris. Circulation. 1976;54:522-523.
6. Cheitlin MD, Hutter AM Jr, Brindis R, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;34:1850.
7. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676-H682. (Pubitemid 36142896)
8. Coumel P. Safety of bepridil: from review of the European data. Am J Cardiol. 1992;69:75D-78D.
9. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007;28:3012-3019. (Pubitemid 350262265)
10. Deckers JW. Epidemiological review of stable angina. In: Fox K, Ferrari R, editors. Heart rate management in stable angina. Abingdon: Taylor & Francis; 2005,pp.1-16.
11. Demontis GC, Moroni A, Gravante B, et al. Functional characterisation and subcellular localisation of HCN1 channels in rabbit retinal rod photoreceptors. J Physiol. 2002;542:89-97. (Pubitemid 35190275)
12. De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani LG. The pharmacoeconomic impact of amlodipine use on coronary artery disease. Pharmacol Res. 2006;54:158-163. (Pubitemid 44038387)
13. Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll Cardiol. 1983;1:574-575. (Pubitemid 13063216)
14. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967-974. (Pubitemid 40695027)
15. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757-1765.
16. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol. 1988;61:1219-1222.
17. EMEA (European Medicines Agency). EPARs for authorised medicinal products for human use. 2007. Available at: http://www.emea.europa.eu/humandocs/Humans/ EPAR/procoralan/procoralan.htm (accessed August 2007).
18. ESC (European Society of Cardiology). The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris. 2006. Available at: http://www.escardio. org/NR/rdonlyres/16E8EA50-50AA-467E-B53E-C55E83F05D8A/0/guidelines-Angina-FT- 2006.pdf (accessed July 2007).
19. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652. (Pubitemid 28108434)
20. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96-103. (Pubitemid 26111912)
21. Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J. 2006;152:860-866. (Pubitemid 44632933)
22. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987;59:26F-32F.
23. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
24. Gandhi MM, Lampe FC, Wood DA. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J. 1995;73:193-198.
25. Gibbons RJ, Abrams J, Chatterjee K, et al; ACC/AHA Task Force on Stable Angina Guidelines. ACC/AHA 2002 guidelines update for the management of patients with chronic stable angina. Available at: http://www.acc.org/qualityandscience/ clinical/guidelines/stable/stable-clean.pdf (accessed July 2007).
26. Griffin SC, Barber JA, Manca A, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ. 2007;334:624.
27. Guth BD, Heusch G, Seitelberger R, Ross J Jr. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 1987;60:738-746. (Pubitemid 17098139)
28. Hanania G, Cambou JP, Guéret P, et al; USIC 2000 Investigators. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart. 2004;90:1404-1410.
29. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927-1936. (Pubitemid 29242807)
30. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477-1482. (Pubitemid 32917338)
31. ISRCTN (International Standard Randomised Controlled Trial Number). Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study. 2008. Available at: http://www.controlledtrials.com/ISRCTN70429960/ ivabradine (accessed February 2008).
32. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85:447-452.
33. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-1494. (Pubitemid 17092823)
34. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351-357. (Pubitemid 34761614)
35. Lacoste LL, Théroux P, Lidón RM, Colucci R, Lam JY. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol. 1994;73:1058-1062.
36. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149-155. (Pubitemid 37465145)
37. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J. 1997;18:1404-1410. (Pubitemid 27389033)
38. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212.
39. Pepine CJ. Angina pectoris in a contemporary population: characteristics and therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther. 1998;12(Suppl. 3):211-216.
40. Perski A, Olsson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123:609-616.
41. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris: The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996;17:76-81. (Pubitemid 26111909)
42. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393-405. (Pubitemid 46425552)
43. Saha M, Marber MS. If at first you don't succeed try...a new target in the treatment of angina. Eur Heart J. 2005;26:2482-2483. (Pubitemid 41677298)
44. Savelieva I, Camm JA. Novel If current inhibitor ivabradine: safety considerations. In: Camm J, Tendera M, editors. Heart rate slowing by If current inhibition. Basel: Karger; 2006, pp. 79-96
45. (Advances in Cardiology, vol 43).
46. Shaw LJ, Merz CN, Pepine CJ, et al; Women's Ischemia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Circulation. 2006;114:894-904. (Pubitemid 44337132)
47. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659-666. (Pubitemid 26023611)
48. Singh BN. Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. Am J Cardiol. 1992;69:68D-74D.
49. Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Therapeut. 2001;6:313-331. (Pubitemid 34141817)
50. Tafreshi MJ, Weinacher AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy. 1999;19:974-978. (Pubitemid 29377315)
51. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529-2536. (Pubitemid 41677303)
52. Tendera M. If inhibition: from pure heart rate reduction to treatment of stable angina. Eur Heart J Suppl. 2005;7(Suppl. H):H3-H6. (Pubitemid 41298037)
53. Tendera M, Fox K, Tardif JC, Ford I. Anti-ischemic and antianginal efficacy of ivabradine, a selective and specific If current inhibitor, in elderly patients with stable angina. Circulation. 2006;114(Suppl. II):715. (Abstract)
54. Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin Drug Saf. 2006;5:667-674. (Pubitemid 44322884)
55. Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol. 1994;73:23-28. (Pubitemid 24019995)
56. Zaza A, Rocchetti M. Regulation of the sinoatrial pacemaker: selective If inhibition by ivabradine. In: Fox K, Ferrari R, editors. Heart rate management in stable angina. Abingdon: Taylor & Francis; 2005, pp. 51-67.